Please assess the completion status of the following clinical trial:

Trial Title: Dose-ranging Study in Patients With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participant had given written informed consent to participate in the study in accordance with local regulations.~* Adult participants 18 years and older with a diagnosis of type 1 diabetes mellitus (T1D) made at least 1 year prior to informed consent.~* Participants were being treated with insulin or insulin analog delivered via continuous subcutaneous insulin infusion (CSII) or multiple daily injection (MDI).~* At the Screening Visit, A1C had to be between 7.0% and 10.0%.~* Females of childbearing potential had to use an adequate method of contraception and have a negative pregnancy test.~Exclusion Criteria:~* Use of antidiabetic agent other than insulin or insulin analog at the time of screening.~* Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to screening.~* Chronic systemic corticosteroid use.~* Type 2 diabetes mellitus (T2DM), or severely uncontrolled T1D as determined by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo-matching sotagliflozin tablets, once daily, orally for 12 weeks.
- Sotagliflozin 75 mg (Type: EXPERIMENTAL): Sotagliflozin 75 mg (one 75 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
- Sotagliflozin 200 mg (Type: EXPERIMENTAL): Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
- Sotagliflozin 400 mg (Type: EXPERIMENTAL): Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).